Revumenib

Menin Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Revumenib is an onp drug in the Menin Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2024. Its mechanism of action is classified as Menin Inhibitors. DrugCentral lists 1 molecular target, including MEN1. Recorded indications include Relapsed or refractory acute leukemia.

• Approval status: onp (first approved 2024 by the FDA).
• Drug class: Menin Inhibitor.
• Mechanism of action: Menin Inhibitors.
• Molecular targets: MEN1 (1 listed in DrugCentral).
• Indications: Relapsed or refractory acute leukemia.
• ATC code: L01XX87 (Other antineoplastic agents).
• Molecular formula: C32H47FN6O4S; molecular weight 630.83 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Relapsed or refractory acute leukemia

Mechanism & targets

• Mechanism of action (MoA): Menin Inhibitors
• Established pharmacologic class: Menin Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Menin	MEN1	inhibitor	IC50 9.82

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2024-11-15	FDA	—	Syndax Pharmaceuticals	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01XX87	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: KMT2A · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Off label use	143.8
Differentiation syndrome	123.6

Chemical structure

• Molecular formula: C₃₂H₄₇FN₆O₄S
• Molecular weight: 630.83 g/mol
• CAS number: —
• InChIKey: FRVSRBKUQZKTOW-UHFFFAOYSA-N
• PubChem CID: 132212657

CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Revumenib used for?

DrugCentral lists the following indications for Revumenib: Relapsed or refractory acute leukemia.

How does Revumenib work?

Revumenib is classified as Menin Inhibitors; its molecular targets in DrugCentral include MEN1 (inhibitor).

When was Revumenib first approved?

Revumenib was first approved by the FDA in 2024.

What drug class does Revumenib belong to?

Revumenib is in the Menin Inhibitor class.

What is the chemical formula of Revumenib?

Revumenib has the molecular formula C32H47FN6O4S and a molecular weight of 630.83 g/mol.

Sources

• DrugCentral drug card 5840 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4650278 — compound record and bioactivity
• PubChem CID 132212657 — chemical identifiers
• FDA UNII LZ0M43NNF2 — substance identity
• DailyMed: FDA labels for Revumenib — current prescribing information (label search)
• UniProt O00255 (MEN1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.